Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Verve Therapeutics is raising $93,999,993.00 in new funding. Sources indicate as part of senior management President and Chief Operating Officer, Andrew Ashe played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Verve Therapeutics

Verve is focused on discovering and developing medicines that safely edit the adult genome and mimic naturally protective gene variants to treat coronary heart disease, the leading cause of death worldwide. Verve brings together two of the biggest breakthroughs in 21st century biomedicine human genetic analysis and gene editing to realize a new future, one of longevity and vitality for tens of millions of people around the globe with or at risk for cardiovascular disease.

To learn more about Verve Therapeutics, visit http://www.vervetx.com/

Contact:
Andrew Ashe, President and Chief Operating Officer
617-603-0070
https://www.linkedin.com/in/andrew-ashe-20418a22/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved